全球妇科药品市场规模、份额、趋势和成长分析报告（2026-2034）

妇科药品市场预计将从 2025 年的 780.6 亿美元成长到 2034 年的 1,219.4 亿美元，2026 年至 2034 年的复合年增长率为 5.08%。

受女性健康意识增强和生殖系统疾病发病率上升的推动，全球妇科药品市场正稳定成长。子宫内膜异位症、卵巢症候群（PCOS）和更年期症状等疾病的出现，推动了对专业妇科药物的需求。医疗保健服务覆盖范围的扩大也进一步促进了全球市场的发展。

关键成长要素包括荷尔蒙疗法的进步和诊断技术的改进。人们对计划生育和生育治疗日益增长的兴趣也促进了药物使用量的增长。此外，医疗保健支出的增加和政府关注孕产妇健康的政策也在推动市场成长。

鑑于标靶治疗和个人化医疗研究的进展，前景依然乐观。新兴市场凭藉着不断完善的医疗基础设施和日益增强的健康意识，蕴藏着巨大的发展机会。由于更安全、更有效的药物配方不断创新，全球妇科市场可望维持长期成长。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球妇科药物市场：依治疗方法

• 市场分析、洞察与预测
• 荷尔蒙疗法
• 非荷尔蒙疗法

第五章：全球妇科药物市场：依适应症划分

• 市场分析、洞察与预测
• 妇科癌症
• 子宫内膜异位症
• 女性不孕症
• 更年期症状
• 妇科感染疾病
• 卵巢症候群
• 避孕（节育）
• 其他的

第六章 全球妇科药品市场：依通路划分

• 市场分析、洞察与预测
• 医院药房
• 零售药房
• 网路药房

第七章 全球妇科药品市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Allergan Plc
  • Amgen Inc
  • Bayer AG
  • Merck & Co. Inc
  • Pfizer Inc
  • Eli Lilly And Company
  • F. Hoffmann-La Roche Ltd
  • Ferring Holding SA
  • TherapeuticsMD Inc
  • AbbVie Inc
  • Pfizer Inc
  • AstraZeneca

The Gynecology Drugs Market size is expected to reach USD 121.94 Billion in 2034 from USD 78.06 Billion (2025) growing at a CAGR of 5.08% during 2026-2034.

The Global Gynecology Drugs Market is growing steadily due to rising awareness about women's health and increasing prevalence of reproductive disorders. Conditions such as endometriosis, polycystic ovary syndrome (PCOS), and menopausal symptoms are driving demand for specialized gynecological medications. Expanding access to healthcare services is further supporting market expansion worldwide.

Major growth drivers include advancements in hormonal therapies and improved diagnostic techniques. Growing emphasis on family planning and fertility treatments is also contributing to increased drug utilization. Additionally, rising healthcare spending and government initiatives focused on maternal health are strengthening market growth.

Future prospects remain positive as research into targeted therapies and personalized treatments advances. Emerging markets are expected to offer substantial opportunities due to improving healthcare infrastructure and rising health awareness. Continued innovation in safer and more effective drug formulations will likely sustain long-term growth in the global gynecology drugs market.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Therapeutics

• Hormonal Therapy
• Non-Hormonal Therapy

By Indication

• Gynecological Cancers
• Endometriosis
• Female Infertility
• Menopausal Disorder
• Gynecology Infections
• Polycystic Ovary Syndrome
• Contraception (Birth Control)
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Allergan plc, Amgen Inc, Bayer AG, Merck Co Inc, Pfizer Inc, Eli Lilly and Company, F HoffmannLa Roche Ltd, Ferring Holding SA, TherapeuticsMD Inc, AbbVie Inc, Pfizer Inc, AstraZeneca
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL GYNECOLOGY DRUGS MARKET: BY THERAPEUTICS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Therapeutics
• 4.2. Hormonal Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Non-Hormonal Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL GYNECOLOGY DRUGS MARKET: BY INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Indication
• 5.2. Gynecological Cancers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Endometriosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Female Infertility Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Menopausal Disorder Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Gynecology Infections Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Polycystic Ovary Syndrome Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Contraception (Birth Control) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.9. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL GYNECOLOGY DRUGS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL GYNECOLOGY DRUGS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Therapeutics
  • 7.2.2 By Indication
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Therapeutics
  • 7.3.2 By Indication
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Therapeutics
  • 7.4.2 By Indication
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Therapeutics
  • 7.5.2 By Indication
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Therapeutics
  • 7.6.2 By Indication
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL GYNECOLOGY DRUGS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Allergan Plc
  • 9.2.2 Amgen Inc
  • 9.2.3 Bayer AG
  • 9.2.4 Merck & Co. Inc
  • 9.2.5 Pfizer Inc
  • 9.2.6 Eli Lilly And Company
  • 9.2.7 F. Hoffmann-La Roche Ltd
  • 9.2.8 Ferring Holding SA
  • 9.2.9 TherapeuticsMD Inc
  • 9.2.10 AbbVie Inc
  • 9.2.11 Pfizer Inc
  • 9.2.12 AstraZeneca